David Li Sells 5,000 Shares of Ingevity (NYSE:NGVT) Stock

Ingevity Corporation (NYSE:NGVT) CEO David Li sold 5,000 shares of the business’s stock in a transaction that occurred on Monday, August 17th. The stock was sold at an average price of $75.83, for a total transaction of $379,150.00. Following the completion of the sale, the chief executive officer owned 120,636 shares in the company, valued at $9,147,827.88. The trade was a 3.98% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Ingevity Stock Down 3.6%

NGVT stock opened at $71.33 on Thursday. The firm has a market cap of $2.45 billion, a PE ratio of 48.53 and a beta of 1.16. Ingevity Corporation has a 12 month low of $45.85 and a 12 month high of $79.29. The company has a debt-to-equity ratio of 22.52, a current ratio of 1.61 and a quick ratio of 1.15. The firm has a 50 day simple moving average of $73.91 and a 200 day simple moving average of $71.82.

Ingevity (NYSE:NGVT) last posted its quarterly earnings results on Wednesday, July 29th. The company reported $1.74 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.33 by $0.41. The firm had revenue of $314.10 million for the quarter, compared to analyst estimates of $312.20 million. Ingevity had a net margin of 4.65% and a return on equity of 284.70%. Ingevity has set its FY 2026 guidance at 5.000-5.450 EPS. Equities research analysts forecast that Ingevity Corporation will post 5.4 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several analysts have issued reports on NGVT shares. Weiss Ratings upgraded Ingevity from a “sell (d-)” rating to a “hold (c-)” rating in a report on Friday, July 31st. Wall Street Zen cut shares of Ingevity from a “strong-buy” rating to a “buy” rating in a report on Saturday, August 1st. Two equities research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company. According to MarketBeat, Ingevity currently has an average rating of “Hold” and a consensus target price of $80.00.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the business. Global Retirement Partners LLC purchased a new stake in Ingevity in the 4th quarter worth about $27,000. Meeder Asset Management Inc. acquired a new position in shares of Ingevity in the 4th quarter valued at about $33,000. Geneos Wealth Management Inc. increased its holdings in shares of Ingevity by 85.8% in the 2nd quarter. Geneos Wealth Management Inc. now owns 838 shares of the company’s stock valued at $36,000 after purchasing an additional 387 shares during the period. Frazier Financial Advisors LLC purchased a new stake in shares of Ingevity in the second quarter worth approximately $37,000. Finally, Headlands Technologies LLC purchased a new stake in shares of Ingevity in the second quarter worth approximately $46,000. Hedge funds and other institutional investors own 91.59% of the company’s stock.

Ingevity Company Profile

Ingevity Corporation, traded as NGVT, is a specialty chemicals and performance materials company headquartered in North Charleston, South Carolina. The company operates two primary business units: Performance Chemicals and Performance Materials. The Performance Chemicals segment produces and markets specialty chemicals derived largely from wood and other natural feedstocks, including rosin acids, tall oil fatty acids and esters, as well as specialty petroleum resins. These products serve a broad range of industries, including paper, adhesives, coatings, oilfield drilling and consumer goods.

The Performance Materials segment develops and manufactures activated carbon products and composites for applications such as automotive emissions control, industrial air and water purification, and spill containment.